{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"MOONRAY-01","nct_id":"NCT06586515","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=moonray-01-nct06586515. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MOONRAY-01","arms":[{"description":"Escalating doses of LY3962673 administered orally.","label":"Phase 1a: LY3962673 Dose Escalation","type":"EXPERIMENTAL"},{"description":"LY3962673 administered orally either alone or in combination with other chemotherapy agents.","label":"Phase 1b: LY3962673 Dose Expansion","type":"EXPERIMENTAL"},{"description":"LY3962673 administered orally","label":"Experimental: Phase 1a: LY3962673 Monotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-03","type":"ESTIMATED"},"conditions":["Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer","Colorectal Cancer"],"enrollment":{"count":630,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"LY3962673","otherNames":[],"type":"DRUG"},{"name":"Cetuximab","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"leucovorin","otherNames":[],"type":"DRUG"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"5-fluorouracil","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-20","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2028-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration","timeFrame":"Baseline through 5 years"},{"measure":"Phase 1a: Number of Participants with DLT","timeFrame":"During the first 28-day cycle of LY3962673 treatment"},{"measure":"Phase 1a: Number of Participants with DLT Equivalent Toxicities","timeFrame":"During the first 28-day cycle of LY3962673 treatment"},{"measure":"Phase 1b: Overall Response Rate (ORR)","timeFrame":"Up to approximately 5 years"},{"measure":"Phase 1b: Best Overall Response (BOR)","timeFrame":"Up to approximately 5 years"},{"measure":"Phase 1b: Duration of Response (DOR)","timeFrame":"Up to approximately 5 years"},{"measure":"Phase 1b: Time to Response (TTR)","timeFrame":"Up to approximately 5 years"},{"measure":"Phase 1b: Disease Control Rate (DCR)","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2024-09-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06586515"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/moonray-01-nct06586515"}